Marinus Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
All right. So thank you again for joining us this afternoon at the JMP Securities Life Science Conference. Excited to have Marinus Pharmaceuticals join us right now. Marinus is a company focused on the commercialization and development of novel therapies for CNS diseases. The company has an approved drug for a rare orphan epilepsy indication, CDKL5 deficiency disorder and also developing its lead candidate, ganaxolone for additional epilepsy and neurological indications.
So excited to be joined by company's CFO and COO, Steve Pfanstiel, and Alex -- sorry. Aimetti, the company's Chief Scientific Officer. Sorry, Alex. Thanks for being here, guys. Really, Steve, turn it over to you for a quick 30-second overview of Marinus, and then we'll go from there.
Yeah, sure. Well, just start quickly. So we are now a commercial stage company. We launched our first product Q3 of last year. We have two full quarters of commercialization under our belt. But also very
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |